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Abstract
Sample pretreatment was optimized to obtain high sequence coverage for human serum
albumin (HSA, 66.5 kDa) when using nano-electrospray ionization quadrupole time-of-flight
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mass spectrometry (nESI-Q-TOF-MS). Use of the final method with trypsin, Lys-C and Glu-C
digests gave a combined coverage of 98.8%. The addition of peptide fractionation resulted in
99.7% coverage. These results were comparable to those obtained previously with matrix-
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assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The
sample pretreatment/nESI-Q-TOF-MS method was also used with collision-induced dissociation
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to analyze HSA digests and to identify peptides that could be employed as internal mass
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EP
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D

calibrants in future studies of modifications to HSA.

Keywords:

Human serum albumin; Sequence coverage; Sample pretreatment; Nano-

electrospray ionization quadrupole time-of-flight mass spectrometry; Collision-induced
dissociation; Internal calibration
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Mass spectrometry (MS) is an important tool for identifying proteins and providing
information on the primary sequences of proteins and their post-translational modifications
(PTMs) [1,2]. Several recent studies have used MS to examine human serum albumin (HSA,

RI
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66.5 kDa) and PTMs such as non-enzymatic glycation that occur on this protein [3-5]. The
effects of such modifications have been of concern given the important role played by HSA in
transporting many low mass substances in blood (e.g., hormones, fatty acids, and drugs) [6].
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Several past studies have utilized matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF-MS) to investigate the structure of HSA and glycated

M
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HSA [2,3,7-12]. Sequence coverages of up to 97.4% have been reached by optimizing the
MALDI matrix and conditions that were used for sample pretreatment; however, obtaining this
level of coverage required multiple enzyme digestions and a series of steps for peptide
fractionation [2].

The purpose of this current study was to determine if more convenient

TE
D

pretreatment conditions could still obtain high sequence coverage for a moderately high mass
protein such as HSA and when using nano-electrospray quadrupole time-of-flight mass
spectrometry (nESI-Q-TOF-MS) for analysis of the digests.

EP

Two pretreatment procedures were initially considered (see Supplementary Material for
more details). Pretreatment Method 1 followed a scheme similar to the previous method used

AC
C

with MALDI-TOF-MS [2] but without any peptide fractionation. In this method, a sample of
HSA was first treated by means of alkylation and reduction, followed by dialysis to remove any
excess reagents. The protein sample was then digested separately with three proteolytic enzymes
(i.e., trypsin, Lys-C and Glu-C) and analyzed by MS. In Pretreatment Method 2, all of the
pretreatment and digestion processes were performed sequentially in a single vial, resulting in
the ability to use lower concentrations of both the protein and pretreatment reagents. The
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pretreatment conditions for alkylation and reduction were similar to those in Pretreatment
Method 1, with some slight variations in the reaction times and temperatures. Also in

and each digest was fractionated by using ZipTipµ-C18 pipette tips.
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Pretreatment Method 2, dialysis was no longer used to remove the excess pretreatment reagents,

Figure 1 and the Supplementary Material summarize the results that were obtained by
nESI-Q-TOF-MS for digests of HSA when using these pretreatment methods. The use of
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Pretreatment Method 1 with a tryptic digest gave 42 identified peptides and a sequence coverage
of 36.9% for HSA, while the Glu-C or Lys-C digests gave sequence coverages of 39.1% or
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32.1% and 43 or 21 identified peptides, respectively. For Pretreatment Method 2, the sequence
coverages were 86.0% for the tryptic digest, 84.1% for Lys-C digest and 78.2% for Glu-C digest,
which corresponded to 104, 52, or 54 identified peptides in these digests. Because there was
both improved sequence coverage and an increase in the number of identified peptides with

TE
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Pretreatment Method 2, this method was selected for use in the remainder of this study.
The results obtained by Pretreatment Method 2, nESI-Q-TOF-MS, and using a single
elution step for peptide fractionation were compared to the results from the previous

EP

pretreatment method that had been used with MALDI-TOF-MS to examine HSA (see
Supplementary Material) [2]. The previous MALDI-TOF-MS method gave sequence coverages

AC
C

of 82.9%, 77.6% or 64.6% and 56, 41, or 28 identified peptides when HSA was digested with
trypsin, Lys-C or Glu-C, respectively, and these digests were fractionated on ZipTipµ-C18 tips
through a series of several elution steps [2]. The approach based on Pretreatment Method 2 and
nESI-Q-TOF-MS, which used a simpler alkylation/reduction protocol and only a single elution
step for peptide fractionation, gave 3.1-13.6% higher sequence coverages for these digests and a
greater number of identifiable peaks (i.e., 11-48 more peptides per digest). The use of multiple
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elution steps for peptide fractionation, as described in the Supplementary Material, gave a small
increase in the sequence coverages for Pretreatment Method 2 and nESI-Q-TOF-MS to levels of
83.2% and 91.5% for tryptic and Glu-C digests and a slight decrease to 72.6% for the Lys-C

RI
PT

digest.

When a single elution step was used for peptide fractionation in Pretreatment Method 2,
the total sequence coverage obtained by nESI-Q-TOF-MS for HSA was 98.8%. This coverage

SC

included 578 out of the 585 amino acids in HSA, with the only excluded region being residues
535-541. This coverage included 56 out of 59 lysines in HSA and all of the arginine residues,
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which were of interest because lysine and arginine are both potential sites for glycation-related
modifications (Note: the three lysines in residues 535-541 that were not included in this coverage
are not major sites for such modifications) [3]. When multiple elution steps were used for
peptide fractionation, the combined digests gave an overall sequence coverage was 99.7%, in

TE
D

which a total of 583 out of 585 residues were now covered. The only missing residues in this
second case came from residues 312-313; however, previous reports have shown that K313 is
highly susceptible to modification by glycation [3].

EP

Both of these situations were an improvement over the previous pretreatment method
used with MALDI-TOF-MS, in which a total sequence coverage of 97.4% was obtained for HSA

AC
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when data were combined for the three enzyme digests [2]. In this prior work, 570 out of the
585 amino acids were included, as well as 54 of the 59 lysines and all of the arginines. In the
missed regions for this previous method, K4, K536, K538, and K541 are not major sites for
glycation-related modifications, but K317 can be an important location for such PTMs [3].
Neither the previous MALDI-TOF-MS method nor the use of Pretreatment Method 2 with nESIQ-TOF-MS and a single elution step for fractionation covered the region 535-541 of HSA.
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However, if the data were combined for nESI-Q-TOF-MS and Pretreatment Method 2 when
using both a single step and multiple steps for peptide fractionation, then all 585 amino acids of
HSA included and effectively 100% coverage was achieved.
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In the previous work with HSA and MALDI-TOF-MS [2], 0.5 µL portions of the
fractionated protein digests (protein concentrations: ~0.822 µg/µL in tryptic digest, ~0.870
µg/µL in Lys-C digest, and ~ 1.25 µg/µL in Glu-C digest) were individually mixed with the

SC

MALDI matrix and spotted onto a plate for MS analysis. These multiple fractions increased the
overall amount of sample that was needed for analysis. Although a 20 µL sample of the purified
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protein digest (protein concentration: ~ 1 µg/µL in each digest) was prepared for use in
Pretreatment Method 2 and nESI-Q-TOF-MS, the sample could be placed directly into the nanoESI emitter and sprayed in nanoliter volumes to obtain a mass spectrum. In addition, the
remaining sample from the nano-ESI emitter could be recovered and stored for future

TE
D

experiments.

Another advantage of the nESI-Q-TOF-MS method over MALDI-TOF-MS was its
ability to perform MS/MS experiments on the digests, such as by using CID to create peptide

EP

fragmentation [13]. This type of experiment was performed on the various digests of HSA to
confirm the identity of the peptides, as demonstrated in Figure 2(a). Some of these peptides were

AC
C

also tested for use as internal m/z calibrants to improve mass accuracy when searching for PTMs
[14,15] like glycation-related modifications [2,3,7-10], as illustrated in Figure 2(b). Around 6-7
unique peptides were selected through these experiments from each type of enzyme digest of
HSA, with each peptide having a relatively high signal intensity (see Supplementary Material).
One of these peptides is shown in Figure 2(a) and corresponded to residues 337-348 and
RHPDYSVVLLLR; this peptide was selected because it contained no lysine residues and would
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not be subject to PTMs at such sites. Other peptides were chosen because they appeared in a
variety of regions in the mass spectra.
These peptides were next used as internal calibrants in the analysis of a separate set of
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HSA digests that were prepared by using trypsin, Lys-C, or Glu-C. A calibrated spectrum of a
Glu-C digest of HSA resulted in a root mean square mass error of 19.9 ppm, with similar results
being obtained with the trypsin and Lys-C digests. This low mass measurement error made it

SC

possible to lower the mass tolerance that was used for sequence analysis (i.e., a previous value of
50 ppm); this change had the advantage of reducing the possibility of false positive matches
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while also improving confidence in the assignment of putative peptides, including those
harboring PTMs. The effect of this change on the sequence coverage was evaluated by using the
internally calibrated mass spectra for the tryptic, Lys-C and Glu-C digests along with a 25 ppm
mass tolerance. Under these conditions, the individual digests had sequence coverages of 79.8%,

TE
D

86.5%, and 78.9% for tryptic, Lys-C and Glu-C digests, with a 96.1% total coverage for the
combined results. These results were comparable to the previous values acquired by MALDITOF-MS [2] and were only slightly lower than the coverages seen earlier with nESI-Q-TOF-MS

EP

when using a 50 ppm mass tolerance and no internal calibration.
In summary, a sample pretreatment was developed for use with nESI-Q-TOF-MS to

AC
C

obtain high sequence coverage for HSA. The combined use of nESI-Q-TOF-MS and the final
pretreatment method with single or multiple elution steps for peptide fractionation gave sequence
coverages of 98.8-99.7% for HSA, with a combined coverage of essentially 100%. It was also
shown how this combined approach could be used with CID to confirm the structures of the
peptides and to select some of these peptides for use as internal calibrants in MS/MS
experiments. Although this study focused on the analysis of HSA by nESI-Q-TOF-MS, the same
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methods could be applied to other proteins with moderately high masses.
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Figure Legends
Figure 1.

Primary sequence of human serum albumin (HSA) [2] and total sequence
coverage of HSA that was obtained with Pretreatment Method 2 and nESI-Q-

RI
PT

TOF-MS when combining the sequence coverages for tryptic (shown in
underline), Lys-C (in bold), and Glu-C (in italics) digests. These results were
obtained using a tolerance level that was equal to a maximum 50.0 ppm mass

(a) MS/MS spectrum for the fragmentation of a peptide with a mass-to-charge
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Figure 2.

SC

difference for each positive match.

ratio of 734 m/z; this peptide corresponded to the 373-348 region of HSA, which
has a sequence of RHPDYSVVLLLR. (b) Mass spectrum of a trypsin-digested
HSA sample, in which peaks that were selected for internal calibration are
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indicated by an asterisk (*).
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Residue No.

Sequence
DAHKSEVAHR

FKDLGEENFK

ALVLIAFAQY

LQQCPFEDHV

41-80

KLVNEVTEFA

KTCVADESAE

NCDKSLHTLF

GDKLCTVATL

81-120

RETYGEMADC

CAKQEPERNE

CFLQHKDDNP

NLPRLVRPEV

121-160

DVMCTAFHDN

EETFLKKYLY

EIARRHPYFY

APELLFFAKR

161-200

YKAAFTECCQ

AADKAACLLP

KLDELRDEGK

ASSAKQRLKC

201-240

ASLQKFGERA

FKAWAVARLS

QRFPKAEFAE

VSKLVTDLTK

241-280

VHTECCHGDL

LECADDRADL

AKYICENQDS

ISSKLKECCE

281-320

KPLLEKSHCI

AEVENDEMPA

DLPSLAADFV

ESKDVCKNYA

321-360

EAKDVFLGMF

LYEYARRHPD

YSVVLLLRLA

KTYETTLEKC

361-400

CAAADPHECY

AKVFDEFKPL

VEEPQNLIKQ

NCELFEQLGE

401-440

YKFQNALLVR

YTKKVPQVST

PTLVEVSRNL

GKVGSKCCKH

441-480

PEAKRMPCAE

DYLSVVLNQL

CVLHEKTPVS

DRVTKCCTES

481-520

LVNRRPCFSA

LEVDETYVPK

EFNAETFTFH

ADICTLSEKE

521-560

RQIKKQTALV

ELVKHKPKAT

KEQLKAVMDD

FAAFVEKCCK

561-585

ADDKETCFAE

EGKKLVASSQ

AALGL

Figure 1
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Mass (m/z)

Figure 2

(b)

